English press releases

Galderma to Present New Clinical Data and High Patient Satisfaction Across Their Portfolio of Dermal Fillers, Collagen Biostimulators and Liquid Neuromodulators at AMWC 2022

Alluzience® (abobotulinumtoxinA, ABO) improves glabellar (frown) lines with high patient satisfaction Positive new data on the efficacy and safety of the new formulation of Sculptra®...

Flowable Recognized in the 2021 Gartner Market Guide for BPA Tools*, for Its Second Consecutive Year

ZURICH–(BUSINESS WIRE)– The Gartner Market Guide for Business Process Automation Tools is a yearly digital publication created by Gartner, a company that delivers actionable, objective...

SES Adds Third Satellite from Thales Alenia Space to Extend Services across Europe, Africa and Asia

Innovative, flexible, software-defined satellite to replace NSS-12 at 57 degrees East to deliver content and connectivity to hundreds of millions at the crossroads of three...

Hytera Announces Global Launch of Next Gen DMR Radio Terminals: H Series

Hytera’s ground-breaking H Series of DMR terminals integrate the latest advances in hardware and software technology to put ultra-reliable, highly ergonomic radios with greatly enhanced...

Publication of definitive end result for Vifor Pharma tender offer

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220327005085/en/ AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR MELBOURNE, Australia & ST....

Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene

– With this reimbursement agreement in place, more than 2,200 people with CF will have PBS-funded access to TRIKAFTA®, including more than 700 who will...

Ipsen Receives Positive CHMP Opinion for Cabometyx® in Radioactive Iodine-refractory Differentiated Thyroid Cancer

Recommendation based on data from the COSMIC-311 Phase III trial, in which Cabometyx® (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death...

Galderma to Highlight Latest Science and Innovation Across Its Product Portfolio at the 2022 AAD Annual Meeting

FORT WORTH, Texas–(BUSINESS WIRE)– Galderma, the leading company solely dedicated to advancing the future of dermatology, announced it will be attending the 2022 American Academy...

Angelini Pharma, a New Partner in Epilepsy

PARIS–(BUSINESS WIRE)– On the occasion of Purple Day (March 26, 2022), an annual international event aimed at raising awareness of epilepsy, Angelini Pharma, international Italian...

ABB Plans to Launch New Share Buyback of up to $3 Billion Following Completion of 2021-2022 Program

Follow-up share buyback program expected to begin in April 2022 and run until 2023 Annual General Meeting. Buyback to exceed remaining $1.2 billion from Power...

Sasol Chemicals Manufacturing Facility Operating on Green External Power

Wind power agreement makes Brunsbüttel, Germany complex the company’s first to obtain all external power from renewable energy Sasol Chemicals, a business unit of Sasol...

ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period

US FDA approval of updated label streamlines the initiation process for the first and only complete long-acting HIV treatment by allowing people to start directly...

Hologic Opens New Innovation Center in France

–The state-of-the-art facility in Aix-en-Provence also serves as the new headquarters of Hologic France– AIX-EN-PROVENCE, France–(BUSINESS WIRE)– Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology...

ABB shareholders approve all proposals at 2022 Annual General Meeting

ZURICH–(BUSINESS WIRE)– The shareholders of ABB have approved all the proposals by the company’s Board of Directors at its 2022 Annual General Meeting. As ABB...

Technip Energies Convenes Its 2022 Annual General Meeting

PARIS–(BUSINESS WIRE)– Technip Energies (PARIS:TE) (the “Company”), a leading Engineering & Technology company for the Energy Transition, today announces the publication of the convening notice...